A new cell treatment to enhance islet transplantation could help maintain healthy blood sugar levels in Type 1 diabetes without the need for multiple transplants of insulin producing cells or regular insulin injections, research suggests. In Type 1 diabetes the insulin-producing cells of the pancreas are destroyed. Insulin injections maintain health but blood glucose levels can be difficult to control. Currently in the UK it...
Scientists at the University of Glasgow and Cancer Research UK Beatson Institute have tested close to 1000 existing medicines and discovered that a cheap drug commonly used to treat parasitic worm infection could be a game-changing treatment for prostate cancer. Prostate cancer is the most common cancer affecting men and the second most common cause of cancer death for men in the UK. The drug,...
Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, announced it has secured follow-on equity investment from Deepbridge Capital totalling £2M, taking Deepbridge’s total investment in Elasmogen to £3.15M. The funding will be used to accelerate the development of the company’s next generation biologics for site-specific delivery and treatment of diseases refractory to existing drug therapies. soloMERs are Elasmogen’s proprietary, humanized versions of drugs originally...
Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, announced that it has entered a collaboration with Bayer AG that aims to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology. Under terms of the agreement, Exscientia will initially work on three projects with targets agreed between both parties. Exscientia may be eligible to receive up to €240 Million, including upfront...
Researchers at the University of Dundee are aiming to make a breakthrough against tuberculosis. A $3million grant from the Bill & Melinda Gates Foundation over the next three years will support the work of Professor Paul Wyatt’s team in the University’s School of Life Sciences. They will identify new treatment options for TB, under the banner of the `LEADS4TB’ programme. TB is a major killer, one of...
Kyowa Kirin Co., Ltd. (TSE: 4151 President and CEO: Masashi Miyamoto, “Kyowa Kirin”)announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinsonʼs disease (PD) experiencing “OFF” time, has been validated by the European Medicines Agency (EMA) and is now under review. This MAA is based on findings from randomised, multi-national, including EU, US...